Stay updated on ARGX-110 with Azacytidine in AML Clinical Trial
Sign up to get notified when there's something new on the ARGX-110 with Azacytidine in AML Clinical Trial page.

Latest updates to the ARGX-110 with Azacytidine in AML Clinical Trial page
- Check2 days agoChange DetectedFooter changes include removal of the HHS Vulnerability Disclosure link and addition of a site revision label 'Revision: v3.3.3' (replacing 'Revision: v3.3.2'). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check9 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check31 days agoChange DetectedThese changes are minor textual updates to the PubMed publications notes and revision labels, with no impact on study details or page functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check38 days agoChange DetectedThe government operating status notice about funding has been removed, while the core study information remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check52 days agoChange DetectedThe Study Details page shows cosmetic/UI adjustments to layout with no changes to core study information such as eligibility criteria, interventions, or outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check81 days agoChange DetectedUpdate includes a funding/status notice and a version bump to v3.2.0; the previous v3.1.0 reference was removed.SummaryDifference3%

- Check88 days agoChange Detected- Updated version from v3.0.2 to v3.1.0. - No other content changes detected.SummaryDifference0.1%

Stay in the know with updates to ARGX-110 with Azacytidine in AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ARGX-110 with Azacytidine in AML Clinical Trial page.